6-Diazo-5-oxo-L-nor-Leucine

6-Diazo-5-oxo-L-nor-Leucine (L-6-Diazo-5-oxonorleucine; DON) is a glutamine antagonist that irreversibly inhibits the catabolic effect of glutamine. 6-Diazo-5-oxo-L-nor-Leucine shows good anticancer activity (especially in pancreatic cancer) and reduces the self-renewal potential and metastatic capacity of tumour cells. 6-Diazo-5-oxo-L-nor-Leucine also possesses antibacterial and antiviral activity[1][2][3].

Product Specifications

CAS Number

[157-03-9]

Product Name Alternative

L-6-Diazo-5-oxonorleucine; DON

UNSPSC

12352211

Hazard Statement

H301+H311+H331

Target

Antibiotic; Bacterial; Glutaminase; Influenza Virus

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/6-diazo-5-oxo-l-nor-leucine.html

Purity

99.98

Solubility

H2O : 25 mg/mL (ultrasonic)

Smiles

N[C@@H](CCC(C=[N+]=[N-])=O)C(O)=O

Molecular Formula

C6H9N3O3

Molecular Weight

171.15

Precautions

H301+H311+H331

References & Citations

[1]Willis RC, et al. The inhibition by 6-diazo-5-oxo-l-norleucine of glutamine catabolism of the cultured human lymphoblast. J Cell Physiol. 1977 Dec;93 (3) :375-82.|[2]Sharma NS, et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest. 2019 Oct 15.|[3]DeWald H A, et al. 6-diazo-5-oxo-l-norleucine, a new tumor-inhibitory substance. 1a preparation of l-, d-and dl-forms1b. Journal of the American Chemical Society, 1958, 80 (15) : 3941-3945.